Abstract: A selectively removable engine anode having a metallic anode base with a threaded configuration disposed proximal to a lower end thereon and on an outer surface, a flanged platform extending radially along a longitudinal length of the base to define an outer flange diameter, and a cantilevered retention member directly coupled to the flanged platform and having a diameter less than the outer flange diameter. The anode includes a galvanic anode with a first anode end coupled to the flanged platform, a second anode free end opposing the first anode end, and an anode length separating the first anode end and the second anode free end, wherein the galvanic anode and the flanged platform encapsulate the cantilevered retention member, the anode base is selectively removably couplable to a plug that is operably configured to be selectively coupled to a marine engine.

Abstract: A selectively removable engine anode having a metallic anode base with a threaded configuration disposed proximal to a lower end thereon and on an outer surface, a flanged platform extending radially along a longitudinal length of the base to define an outer flange diameter, and a cantilevered retention member directly coupled to the flanged platform and having a diameter less than the outer flange diameter. The anode includes a galvanic anode with a first anode end coupled to the flanged platform, a second anode free end opposing the first anode end, and an anode length separating the first anode end and the second anode free end, wherein the galvanic anode and the flanged platform encapsulate the cantilevered retention member, the anode base is selectively removably couplable to a plug that is operably configured to be selectively coupled to a marine engine.

Abstract: The present invention relates to the use of alpha-1-antitrypsin for the preparation of effective drugs for the treatment of chronic fatigue syndrome. In addition, the present invention relates to the use of plasma or other therapeutic forms with an alpha-1-antitrypsin content sufficient to obtain a dose of 6 mg or more of alpha-1-antitrypsin per kg of body weight at a frequency of between 1 and 31 days.

Abstract: The present invention relates to the use of alpha-1-antitrypsin for the preparation of effective drugs for the treatment of chronic fatigue syndrome. In addition, the present invention relates to the use of plasma or other therapeutic forms with an alpha-1-antitrypsin content sufficient to obtain a dose of 6 mg or more of alpha-1-antitrypsin per kg of body weight at a frequency of between 1 and 31 days.